CLAZF.US Claritas Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Oct 6, 2026
0.0001 0.0001
Market cap
USD 3.66K
P/E
-
P/B
0.00x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.

Is CLAZF.US undervalued?

Graham number

The Graham number of Claritas Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Claritas Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Claritas Pharmaceuticals Inc yet.

Claritas Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Claritas Pharmaceuticals Inc

Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.

Full company profile